New drug cocktail aims to shrink stomach tumors in Mid-Stage trial

NCT ID NCT06628310

Ongoing Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This Phase 2 study tests a new drug, telisotuzumab adizutecan (ABBV-400), combined with standard chemotherapy and an immunotherapy drug for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 adults will receive either the new combo or standard treatment to see which works better at slowing cancer growth. The study will also find the best dose of the new drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Telisotuzumab adizutecan (ABBV-400) combined with budigalimab, fluorouracil, and leucovorin
What this could lead to: If successful, this could offer a new first-line treatment option for people with advanced stomach or esophageal cancer, potentially improving how long they live without their cancer growing.
What could go wrong: This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. The new drug combination may cause side effects or not work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC ADENOCARCINOMA

Contacts and locations

Locations

AdventHealth Orlando /ID# 268561

Orlando, Florida, 32803, United States
Aichi Cancer Center /ID# 268124

Nagoya, Aichi-ken, 464-8681, Japan
Algemeen Ziekenhuis klina /ID# 268754

Brasschaat, Antwerpen, 2930, Belgium
Barts Health NHS Trust /ID# 270796

London, Greater London, E1 2ES, United Kingdom
Beijing Cancer Hospital /ID# 268455

Beijing, Beijing Municipality, 100142, China
CHU de Liege /ID# 270223

Liège, 4000, Belgium
Cancer Hospital Chinese Academy of Medical Sciences(Langfang) /ID# 277479

Langfang, Hebei, 065000, China
Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 268763

Montreal, Quebec, H2X 0C1, Canada
China Medical University Hospital /ID# 267667

Taichung, 40447, Taiwan
City Of Hope - Atlanta /ID# 280646

Newnan, Georgia, 30265, United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 272630

Irvine, California, 92618, United States
City of Hope National Medical Center /ID# 268690

Duarte, California, 91010, United States
Complexo Hospitalario Universitario de Ourense /ID# 270042

Ourense, 32005, Spain
Duke University Medical Center /ID# 268186

Durham, North Carolina, 27710, United States
Hadassah Medical Center-Hebrew University /ID# 267753

Jerusalem, 91120, Israel
Haematologisch-Onkologische Praxis Eppendorf /ID# 268024

Hamburg, 20249, Germany
Harbin Medical University Cancer Hospital /ID# 268452

Harbin, Heilongjiang, 150081, China
Hattiesburg Clinic /ID# 268572

Hattiesburg, Mississippi, 39401, United States
Hospital Clinico Universitario de Valencia /ID# 270040

Valencia, 46010, Spain
Hospital General Universitario Gregorio Maranon /ID# 270037

Madrid, 28007, Spain
Hospital Universitario de Navarra /ID# 270119

Pamplona, Navarre, 31008, Spain
Jewish General Hospital /ID# 268413

Montreal, Quebec, H3T 1E2, Canada
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 267672

Kaohsiung City, 807, Taiwan
Krankenhaus Nordwest /ID# 268462

Frankfurt am Main, Hesse, 60488, Germany
Linkou Chang Gung Memorial Hospital /ID# 267668

Taoyuan City, 333, Taiwan
Meir Medical Center /ID# 267998

Kefar Sava, Central District, 4428164, Israel
Millennium Physicians /ID# 268540

Houston, Texas, 77090, United States
NHS Tayside Health Board /ID# 270799

Dundee, DD2 1SG, United Kingdom
National Cancer Center Hospital /ID# 268648

Chuo-Ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East /ID# 268083

Kashiwa-shi, Chiba, 277-8577, Japan
National Cheng Kung University Hospital /ID# 267669

Tainan, 704, Taiwan
National Taiwan University Hospital /ID# 267666

Taipei, 100, Taiwan
Oxford University Hospital NHS Trust /ID# 274614

Oxford, Oxfordshire, OX3 7LE, United Kingdom
Pan American Center for Oncology Trials - Rio Piedras /ID# 268833

Rio Piedras, 00935, Puerto Rico
Princess Margaret Cancer Centre /ID# 268277

Toronto, Ontario, M5G 2M9, Canada
Queen Elizabeth Hospital Birmingham /ID# 271199

Birmingham, B15 2TH, United Kingdom
Shaare Zedek Medical Center /ID# 267752

Jerusalem, 9103102, Israel
Shizuoka Cancer Center /ID# 268123

Sunto-gun, Shizuoka, 411-8777, Japan
Soroka Medical Center /ID# 268301

Beersheba, Southern District, 8410101, Israel
TUM Klinikum rechts der Isar /ID# 267792

Munich, Bavaria, 81675, Germany
Taipei Veterans General Hospital /ID# 267664

Taipei, 112, Taiwan
Tel Aviv Sourasky Medical Center /ID# 267755

Tel Aviv, Tel Aviv, 6423906, Israel
The Cancer Institute Hospital Of JFCR /ID# 268656

Koto-ku, Tokyo, 135-8550, Japan
The first Affiliated Hospital, Zhejiang University School of Medicine. /ID# 268782

Hangzhou, Zhejiang, 310003, China
UCLA - Santa Monica /ID# 270024

Santa Monica, California, 90404, United States
Union Hospital - Tongji Medical College /ID# 268796

Wuhan, Hubei, 430022, China
Universitaetsklinikum Freiburg /ID# 270407

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Universitaetsklinikum Leipzig /ID# 270432

Leipzig, Saxony, 04103, Germany
Universitair Ziekenhuis Leuven /ID# 269957

Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.